Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.41 USD | +6.16% | +2.99% | +135.93% |
04-17 | Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer | CI |
03-28 | Sector Update: Health Care Stocks Advance Premarket Thursday | MT |
Business Summary
Number of employees: 110
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antisense Oligonucleotide
100.0
%
| 12 | 100.0 % | 9 | 100.0 % | -29.22% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 12 | 100.0 % | 9 | 100.0 % | -29.22% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Edward Kaye
CEO | Chief Executive Officer | 75 | 17-09-30 |
Isabel Aznarez
FOU | Founder | 52 | 14-05-31 |
Stephen Tulipano
DFI | Director of Finance/CFO | 65 | 19-02-28 |
Barry Ticho
CTO | Chief Tech/Sci/R&D Officer | 64 | 17-09-30 |
Huw Nash
COO | Chief Operating Officer | 57 | 14-09-30 |
Eric Rojas
IRC | Investor Relations Contact | - | - |
Jonathan Allan
LAW | General Counsel | - | - |
Shamim Ruff
LAW | General Counsel | 64 | 18-11-30 |
Joan Wood
HRO | Human Resources Officer | - | 19-10-15 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Arthur Levin
BRD | Director/Board Member | 70 | 15-08-31 |
Edward Kaye
CEO | Chief Executive Officer | 75 | 17-09-30 |
Seth Harrison
CHM | Chairman | 63 | 15-06-30 |
Ian Smith
BRD | Director/Board Member | 58 | 23-09-18 |
Garry Menzel
BRD | Director/Board Member | 59 | 20-08-12 |
Julie Smith
BRD | Director/Board Member | 53 | 20-06-03 |
Director/Board Member | 52 | 19-06-13 | |
Arthur Tzianabos
BRD | Director/Board Member | 60 | 18-09-16 |
Adrian Krainer
FOU | Founder | 65 | 14-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 52,117,499 | 49,727,994 ( 95.42 %) | 0 | 95.42 % |
Company contact information
Stoke Therapeutics, Inc.
45 Wiggins Avenue
01730, Bedford
+781 430 8200
http://www.stoketherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+135.93% | 647M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- STOK Stock
- Company Stoke Therapeutics, Inc.